SCHEMBL5757803

SCHEMBL5757803

COc1ccc2cc(C3CCNC(C)C3)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 2/20 0.47
HTR2C P28335 4/20 0.47
HTR2A P28223 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2A6 P11509 1/20 0.40
FDFT1 P37268 1/20 0.39
PLG P00747 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38
HTR1A P08908 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
NISCH Q9Y2I1 1/20 0.38
MAOA P21397 2/20 0.36
KDM1A O60341 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7970364 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3HTR2CHTR2A
SCHEMBL5758612 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3HTR2CHTR2A
SCHEMBL5758608 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3HTR2CHTR2A
SCHEMBL7970359 1.00 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3HTR2CHTR2A
Hydrochloric Acid SCHEMBL7096369 0.99 HTR2C (0.48) SLC6A2SLC6A4SLC6A3HTR2CHTR2A
SCHEMBL18618469 0.86 KDM1A (0.44) HTR2CPLGMEN1KMT2APOLB
SCHEMBL7119720 0.84 HTR2C (0.68) SLC6A2SLC6A4SLC6A3HTR2CHTR2A
SCHEMBL7119723 0.84 HTR2C (0.68) SLC6A2SLC6A4SLC6A3HTR2CHTR2A
SCHEMBL7119711 0.84 HTR2C (0.68) SLC6A2SLC6A4SLC6A3HTR2CHTR2A
SCHEMBL5090671 0.83 SLC6A4 (0.46) SLC6A2SLC6A4SLC6A3HTR2CPLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144898-B2 Indole derivatives for the treatment of depression and anxiety ELI LILLY AND COMPANY (US) 2006-12-05 US disclosed
EP-1242411-B1 INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY LILLY CO ELI (US) 2006-03-08 EP disclosed
US-20040006229-A1 Indole derivatives for the treatment of depression and anxiety ELI LILLY AND COMPANY 2004-01-08 US disclosed
EP-1242411-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY ELI LILLY AND COMPANY (US) 2002-09-25 EP disclosed
US-6303627-B1 FOR THERAPY OF PHYSIOLOGICAL AND PSYCHOLOGICAL DISORDERS ELI LILLY AND COMPANY 2001-10-16 US disclosed
WO-2001046181-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY ELI LILLY AND COMPANY (US) 2001-06-28 WO disclosed
WO-1999065487-A1 INHIBITORS OF SEROTONIN REUPTAKE ELI LILLY AND COMPANY (US) 1999-12-23 WO disclosed
EP-0965587-A1 Tetrahydropyridinyl- and piperidinyl Inhibitors of serotonin reuptake ELI LILLY AND COMPANY (US) 1999-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006229-A1 Indole derivatives for the treatment of depression and anxiety IDO1, TPH1, IDO2 SLC6A2 68/4885SLC6A4 45/4885SLC6A3 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.